Debora Santoro

A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome

David G. Sweet, M. Turner, Zbyněk Straňák et al. · Archives of Disease in Childhood Fetal & Neonatal · 2017 · 72 citations · Full text

Medicine, Pediatrics, Pharmacology +17

Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study

Dave Singh, Aida Emirova, Catherine Francisco et al. · Respiratory Research · 2020 · 46 citations · Full text

Medicine, Clinical Sciences, Pharmacology +16

A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients

Dave Singh, Brian Leaker, Malcolm Boyce et al. · Pulmonary Pharmacology & Therapeutics · 2016 · 45 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

A Randomized, Controlled Trial to Investigate the Efficacy of Nebulized Poractant Alfa in Premature Babies with Respiratory Distress Syndrome

Carlo Dani, Gyula Tálosi, Annalisa Piccinno et al. · The Journal of Pediatrics · 2022 · 44 citations · Full text

Medicine, Pediatrics, Pharmacotherapy +17

Synthetic Surfactant CHF5633 Compared with Poractant Alfa in the Treatment of Neonatal Respiratory Distress Syndrome: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial

Rangasamy Ramanathan, Manoj Biniwale, Krishnamurthy Sekar et al. · The Journal of Pediatrics · 2020 · 43 citations

Medicine, Pediatrics, Pharmacology +17